Active Crohn's clinical trials

• ADVANCE

  Rizankizumab (anti-IL 23) 

  An open label extension study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy 

• MOTIVATE

  Rizankizumab (anti-IL 23)  

  A study enrolling moderate to severe Crohn’s disease patients that have failed one or more biologic therapy

• U-Exceed

  Upadactinib (anti-Jak 1)

  A study enrolling moderate to severe active Crohn's disease patients who have inadequately responded or are intolerant of prior biologic treatment

• Yellowstone

  Oral Ozanimod (S1P1 and S1P5 agonist)

  Phase 3 study of oral small molecule for moderate to severe active Crohn's disease

• POWER

  Stelara (anti-IL 12/23)

  A Phase 3b study enrolling moderate to severely active Crohn’s disease patients for intravenous re-induction therapy with Ustekinumab 

   

• Explorer

   Vedolizumab IV, Adalimumab SC, and oral Methotrexate  

  An open label, triple therapy, phase 4 study for early treatment of Crohn’s disease

• GALAXI

  Guselkumab (anti-IL 23) 

  A phase 2/3 study enrolling moderate to severe Crohn’s disease patients or fistulizing Crohn’s disease patients, with past colitis, ileitis, or ileocolitis

Active Ulcerative Colitis clinical trials

• INSPIRE

  Risankizumab (anti-IL 23) 

  A study enrolling moderate to severe active ulcerative colitis patients who have failed a prior biologic treatment

• U-Achieve

  Upadacitinib (anti-Jak 1) 

  A study enrolling moderate to severe ulcerative colitis patients that failed one or more biologic therapy

• QUASAR

  Guselkumab (anti-IL 23)

  A Phase 2b/3 study of the efficacy and safety of Guselkumab in participants with moderately to severely active ulcerative colitis

   

Miscellaneous trials

• TARGET

  A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease